CD274 and non-small cell lung carcinoma: From a report published by the CRN in 2021 we know that approximately 30% of NSCLC patients was treated with immunotherapy (mainly PD-1/PD-L1 inhibitors) in 2020, but also that approximately 25% of the patients did not receive any anti-cancer treatment at all (26).